학술논문
Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria.
Document Type
Article
Author
Source
Subject
*OMALIZUMAB
*HISTAMINE
*BASOPHILS
*URTICARIA
*OFF-label use (Drugs)
*
*
*
*
Language
ISSN
0954-7894
Abstract
A study published in the journal Clinical & Experimental Allergy found that a positive basophil histamine release assay (BHRA) can help identify patients with type IIb chronic spontaneous urticaria (CSU) who are less likely to respond to standard-dosed omalizumab treatment. CSU patients with type IIb autoimmunity have a higher disease severity and are more refractory to antihistamines and omalizumab. The study also found that BHRA positivity occurs in approximately one out of seven CSU patients and may be used as a predictor of a poorer response to omalizumab, indicating the need for off-label use in these patients. [Extracted from the article]